In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on ProQR (PRQR – Research Report), with a price target of ...

ProQR (PRQR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP ...

To begin the process of gene editing using CRISPR technology, employ a guide RNA to pinpoint the desired sequence, followed ...

In a paper published in Science Bulletin, a Chinese team of scientists conducted a GFP-activation assay screening 13 Cas12b ...

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...

Recent research published in the journal “Science Bulletin” detailed the creation of a tool called ChCas12b that can ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...

In molecular biology, RNA modifications were traditionally associated with static structural components like rRNAs and tRNAs. However, advancements such as antibody immunoprecipitation and ...

This study is led by Professor Yongming Wang's research team from Fudan University, in collaboration with the team led by Professor Renjie Chai from ...

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through ...